Global Compounding Chemotherapy Market Research Report—Forecast till 2027
As per this report, Global Compounding Chemotherapy Market is anticipated to exhibit a CAGR of 6.04% during the review period of 2020 to 2027, to surpass USD 635.58 Million by 2027. The global market growth is driven by the surged incidences of cancer, increasing expenditure on medicine & science and reimbursements, and increased health benefits. Further, the Compounding chemotherapy market is attributed to the emerging technical advancements, innovations, and strategies to cater to the demands of clinicians.
The global Compounding Chemotherapy Market is expected to witness substantial market growth owing to the highest market contribution in 2019. The rising opioid scarcity is predicted to increase the demand for compounding chemotherapy globally for compounding chemotherapy. The growth of the market is driven by the benefits of easy-to-use medicines, allowing alternative dosage types to access expired medicines, and making medicines allergen safe. Additionally, hospitals and other healthcare providers are allowing customers to purchase medications that are compounded.
Global Compounding Chemotherapy Market has been classified in terms of Dose, Compounding Type, Delivery Method, Sterility, Technology, Compounder Type, and Application.
Global Compounding Chemotherapy Market in terms of the dose has been bifurcated into chemotherapeutic and non-chemotherapeutics. The global compounding chemotherapy market, by compounding type, has been classified into pharmaceutical ingredient alteration (PIA), currently unavailable pharmaceutical manufacturing (CUPM), and pharmaceutical dosage alteration (PDA). The PDA segment is evaluated to register a fastest growth rate during the forecast period. Based on the delivery method, the global market has been divided into gravimetric automated compounding devices (weight-based) and volumetric automated compounding devices (volume-based).
Based on the global compounding chemotherapy market, has been bifurcated into sterile and non-sterile. The sterile is expected to lead the market owing to the largest share of 56.0% in 2019.
Region-specific analysis of Global Compounding Chemotherapy Market, based on region, has been classified into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is likely to drive the largest market owing to the surge in cancer patients, an increase in health care rates, and the growing requirement for treatment with chemotherapy in the area. The regional market has been classified into North America and Latin America, with the North American market further divided into the US and Canada.
The European compounding chemotherapy market has been classified into Western Europe and Eastern Europe. The Western Europe compounding chemotherapy market is spread across Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. The regional market has been driven by the government-based research program aimed at curing the rising number of cancer cases and increased health spending pushes the growth of the regional chemotherapy market.
The Key Players in the Global Compounding Chemotherapy Market include Braun Melsungen AG, Pfizer Inc., Baxter, Grifols SA, The Metrix Company, Added Pharma, Equashield, Millers Pharmacy, Comecer S.P.A., Omnicell, Icon group, Dedalus Group, Arxium, Sterline S.R.L., and Loccioni.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.